{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:21:05Z","timestamp":1789698065190,"version":"4.0.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.eprac.2023.09.007","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T02:21:17Z","timestamp":1695176477000},"page":"986-993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Overnight 1-mg Dexamethasone Suppression Test for Screening Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS): What Happens when Serum Dexamethasone Is Below Cutoff? How Frequent Is it?"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5748-4593","authenticated-orcid":false,"given":"Denise G.","family":"Farinelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6492-0522","authenticated-orcid":false,"given":"Kelly C.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian F.","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4350-1070","authenticated-orcid":false,"given":"Claudio E.","family":"Kater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2023.09.007_bib1","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1210\/jcem-20-12-1539","article-title":"Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing syndrome","volume":"20","author":"Liddle","year":"1960","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2023.09.007_bib2","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/archinte.1965.03870020012006","article-title":"Diagnosis of Cushing syndrome; single dose dexamethasone suppression test","volume":"116","author":"Nugent","year":"1965","journal-title":"Arch Intern Med"},{"issue":"30","key":"10.1016\/j.eprac.2023.09.007_bib3","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1001\/jama.1965.03090090026005","article-title":"A\u00a0rapid screening test for Cushing syndrome","volume":"193","author":"Pavlatos","year":"1965","journal-title":"JAMA"},{"issue":"Pt 3","key":"10.1016\/j.eprac.2023.09.007_bib4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/000456329703400302","article-title":"Evidence for the low dose dexamethasone suppression test to screen for Cushing syndrome -- recommendations for a protocol for biochemistry laboratories","volume":"34","author":"Wood","year":"1997","journal-title":"Ann Clin Biochem"},{"issue":"5","key":"10.1016\/j.eprac.2023.09.007_bib5","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of cushing syndrome: an endocrine society clinical practice guideline","volume":"93","author":"Nieman","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2023.09.007_bib6","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1093\/ejendo\/lvad066","article-title":"European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"189","author":"Fassnacht","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.eprac.2023.09.007_bib7","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1210\/jc.2007-0596","article-title":"Specificity of first-line tests for the diagnosis of Cushing syndrome: assessment in a large series","volume":"92","author":"Pecori Giraldi","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2023.09.007_bib8","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/EJE-17-0078","article-title":"Simultaneous assay of cortisol and dexamethasone improved diagnostic accuracy of the dexamethasone suppression test","volume":"176","author":"Ueland","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1016\/j.eprac.2023.09.007_bib9","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/clinchem\/hvab056","article-title":"Method-specific cortisol, and dexamethasone thresholds increase clinical specificity of the dexamethasone suppression test for Cushing syndrome","volume":"67","author":"Vogg","year":"2021","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.eprac.2023.09.007_bib10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1530\/EJE-13-0702","article-title":"Differentiating between Cushing disease and pseudo-Cushing syndrome: comparison of four tests","volume":"170","author":"Alwani","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2023.09.007_bib11","doi-asserted-by":"crossref","first-page":"R205","DOI":"10.1530\/EJE-16-0946","article-title":"Diagnosis of endocrine disease: differentiation of pathologic\/neoplastic hypercortisolism (Cushing syndrome) from physiologic\/non-neoplastic hypercortisolism (formerly known as pseudo-Cushing syndrome)","volume":"176","author":"Findling","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2023.09.007_bib12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1590\/S1676-24442011000500003","article-title":"Development of a radioimmunoassay for serum dexamethasone as an aid to diagnose Cushing\u2019s syndrome. (Port)","volume":"47","author":"Hayashi","year":"2011","journal-title":"J\u00a0Bras Patol Med Lab"},{"issue":"8","key":"10.1016\/j.eprac.2023.09.007_bib13","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s40618-020-01197-6","article-title":"Dexamethasone measurement during low-dose suppression test for suspected hypercortisolism: threshold development with and validation","volume":"43","author":"Ceccato","year":"2020","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"3","key":"10.1016\/j.eprac.2023.09.007_bib14","first-page":"125","article-title":"A\u00a0radioimmunoassay method to measure serum cortisol (port)","volume":"15","author":"Vieira","year":"1979","journal-title":"Rev Bras Patol Clin"},{"issue":"2","key":"10.1016\/j.eprac.2023.09.007_bib15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1530\/EC-12-0047","article-title":"Association between posttest dexamethasone and cortisol concentrations in the 1 mg overnight dexamethasone suppression test","volume":"1","author":"Asvold","year":"2012","journal-title":"Endocr Connect"},{"issue":"3","key":"10.1016\/j.eprac.2023.09.007_bib16","first-page":"259","article-title":"Serum cortisol levels via radioimmunoassay vs liquid chromatography mass spectrophotometry in healthy control subjects and patients with adrenal incidentalomas","volume":"49","author":"Huayllas","year":"2018","journal-title":"Lab Med"},{"issue":"2","key":"10.1016\/j.eprac.2023.09.007_bib17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/cpt1975182205","article-title":"Bioavailability of oral dexamethasone","volume":"18","author":"Duggan","year":"1975","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.eprac.2023.09.007_bib18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","article-title":"Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids","volume":"44","author":"Czock","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eprac.2023.09.007_bib19","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1007\/s11095-015-1752-9","article-title":"The pharmacokinetics of the CYP3A substrate midazolam in morbidly obese patients before and one year after bariatric surgery","volume":"32","author":"Brill","year":"2005","journal-title":"Pharm Res (N Y)"},{"issue":"4","key":"10.1016\/j.eprac.2023.09.007_bib20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.bbrc.2016.03.012","article-title":"Modeling of drug-mediated CYP3A4 induction by using human iPS cell-derived enterocyte-like cells","volume":"472","author":"Negoro","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.eprac.2023.09.007_bib21","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/138920008784220664","article-title":"Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4","volume":"9","author":"Zhou","year":"2008","journal-title":"Curr Drug Metab"},{"issue":"6","key":"10.1016\/j.eprac.2023.09.007_bib22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/FTD.0b013e31815c16f5","article-title":"Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring","volume":"29","author":"Zhou","year":"2007","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.eprac.2023.09.007_bib23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","article-title":"Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies","volume":"88","author":"Fiest","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.eprac.2023.09.007_bib24","first-page":"391","article-title":"The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects","volume":"76","author":"Lynch","year":"2007","journal-title":"Am Fam Physician"},{"issue":"5","key":"10.1016\/j.eprac.2023.09.007_bib25","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1067\/mcp.2000.110772","article-title":"The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect","volume":"68","author":"Varis","year":"2000","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.eprac.2023.09.007_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/bdd.2173","article-title":"A\u00a0comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys","volume":"40","author":"Tahara","year":"2019","journal-title":"Biopharm Drug Dispos"},{"issue":"5","key":"10.1016\/j.eprac.2023.09.007_bib27","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/jcph.1391","article-title":"4\u03b2-Hydroxycholesterol as an endogenous biomarker for CYP3A activity: literature review and critical evaluation","volume":"59","author":"Penzak","year":"2019","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.eprac.2023.09.007_bib28","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0022-3565(24)36788-6","article-title":"Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites","volume":"282","author":"Sutton","year":"1997","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"8","key":"10.1016\/j.eprac.2023.09.007_bib29","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0006-2952(97)00100-7","article-title":"Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A","volume":"53","author":"Chiba","year":"1997","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.eprac.2023.09.007_bib30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jsbmb.2018.09.003","article-title":"The serum vitamin D metabolome: what we know and what is still to discover","volume":"186","author":"Tuckey","year":"2019","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"issue":"1","key":"10.1016\/j.eprac.2023.09.007_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2021.101519","article-title":"Biochemical diagnosis of Cushing's disease: screening and confirmatory testing","volume":"35","author":"Petersenn","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2023.09.007_bib32","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40262-021-01001-5","article-title":"Drug-metabolizing cytochrome P450 enzymes have multifarious influences on treatment outcomes","volume":"60","author":"Song","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.eprac.2023.09.007_bib33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0022-3956(02)00012-2","article-title":"Hypercortisolemia decreases dexamethasone half-life in rabbit","volume":"36","author":"Stokes","year":"2002","journal-title":"J\u00a0Psychiatr Res"},{"issue":"2","key":"10.1016\/j.eprac.2023.09.007_bib34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1124\/mol.58.2.361","article-title":"Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators","volume":"58","author":"Pascussi","year":"2000","journal-title":"Mol Pharmacol"},{"issue":"6","key":"10.1016\/j.eprac.2023.09.007_bib35","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/cen.13803","article-title":"Extensive clinical experience: hypothalamic-pituitary-adrenal axis recovery after adrenalectomy for corticotropin-independent cortisol excess","volume":"89","author":"Hurtado","year":"2018","journal-title":"Clin Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2023.09.007_bib36","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40618-017-0788-6","article-title":"Predictability of hypoadrenalism occurrence and duration after adrenalectomy for ACTH-independent hypercortisolism","volume":"41","author":"Morelli","year":"2018","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"53","key":"10.1016\/j.eprac.2023.09.007_bib37","doi-asserted-by":"crossref","first-page":"e298","DOI":"10.3346\/jkms.2018.33.e298","article-title":"Assessment of hepatic cytochrome P450 3A activity using metabolic markers in patients with renal impairment","volume":"33","author":"Kim","year":"2018","journal-title":"J\u00a0Korean Med Sci"},{"issue":"6","key":"10.1016\/j.eprac.2023.09.007_bib38","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1053\/jhep.2001.29306","article-title":"Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts","volume":"34","author":"Chalasani","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.eprac.2023.09.007_bib39","doi-asserted-by":"crossref","first-page":"396","DOI":"10.12659\/MSM.892044","article-title":"Serum alanine transaminase total bilirubin concentrations predict CYP3A activity as measured by midazolam and 1\u2019-hydroxylation","volume":"21","author":"He","year":"2015","journal-title":"Med Sci Monit"},{"issue":"7","key":"10.1016\/j.eprac.2023.09.007_bib40","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1021\/acs.molpharmaceut.8b00159","article-title":"Nonalcoholic fatty liver disease and diabetes are associated with decreased CYP3A4 protein expression and activity in human liver","volume":"15","author":"Jamwal","year":"2018","journal-title":"Mol Pharm"},{"issue":"5","key":"10.1016\/j.eprac.2023.09.007_bib41","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s11102-022-01222-2","article-title":"How to rule out non-neoplastic hypercortisolemia (previously known as pseudo-cushing)","volume":"25","author":"Scaroni","year":"2022","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.eprac.2023.09.007_bib42","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/EC-19-0435","article-title":"Altogether to Beat Cushing\u2019s Syndrome (ABC) study group. Approach to patients with pseudo-Cushing\u2019s states","volume":"9","author":"Scaroni","year":"2020","journal-title":"Endocr Connect"},{"issue":"1","key":"10.1016\/j.eprac.2023.09.007_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01059339","article-title":"Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics","volume":"9","author":"Rose","year":"1981","journal-title":"J\u00a0Pharmacokinet Biopharm"},{"key":"10.1016\/j.eprac.2023.09.007_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7742(08)00001-9","article-title":"Gender differences in pharmacological response","volume":"83","author":"Anderson","year":"2008","journal-title":"Int Rev Neurobiol"},{"issue":"3","key":"10.1016\/j.eprac.2023.09.007_bib45","first-page":"319","article-title":"Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. III. Influence of CYP genetic polymorphism on population differentiation of drug metabolism phenotype","volume":"65","author":"Tomaszewski","year":"2008","journal-title":"Acta Pol Pharm"},{"issue":"5","key":"10.1016\/j.eprac.2023.09.007_bib46","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1517\/17425255.2016.1163337","article-title":"CYP3A activity: towards dose adaptation to the individual","volume":"12","author":"Hohmann","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2300561X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2300561X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:15:38Z","timestamp":1761516938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2300561X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1530891X2300561X"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2023.09.007","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overnight 1-mg Dexamethasone Suppression Test for Screening Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS): What Happens when Serum Dexamethasone Is Below Cutoff? How Frequent Is it?","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2023.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}